Rübig E, Stypmann J, Van Slyke P, Dumont DJ, Spieker T, Buscher K, Reuter S, Goerge T, Pavenstädt H, Kümpers P. Sci Rep. 2016 Feb 25;6:22111. https://www.ncbi.nlm.nih.gov/pubmed/26911791
Thamm K, Njau F, Van Slyke P, Dumont DJ, Park JK, Haller H, David S. World J Transplant. 2016 Sep 24;6(3):573-82. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036127/
Vasomune Therapeutics is a private biotechnology company developing Pegevongitide (AV-001), a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor. Activation of the Tie2 receptor by Pegevongitide plays a critical role in improving vascular stability, barrier integrity and endothelial quiescence.